Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Liabilities: 2016-2025

Historic Total Liabilities for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $300.5 million.

  • UroGen Pharma's Total Liabilities rose 8.69% to $300.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $300.5 million, marking a year-over-year increase of 8.69%. This contributed to the annual value of $294.5 million for FY2024, which is 20.94% up from last year.
  • UroGen Pharma's Total Liabilities amounted to $300.5 million in Q3 2025, which was down 0.54% from $302.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Total Liabilities ranged from a high of $302.1 million in Q2 2025 and a low of $20.9 million during Q1 2021.
  • In the last 3 years, UroGen Pharma's Total Liabilities had a median value of $251.5 million in 2024 and averaged $263.8 million.
  • Data for UroGen Pharma's Total Liabilities shows a peak YoY surged of 773.63% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows UroGen Pharma's Total Liabilities stood at $111.3 million in 2021, then surged by 102.08% to $225.0 million in 2022, then rose by 8.24% to $243.5 million in 2023, then rose by 20.94% to $294.5 million in 2024, then rose by 8.69% to $300.5 million in 2025.
  • Its Total Liabilities stands at $300.5 million for Q3 2025, versus $302.1 million for Q2 2025 and $294.1 million for Q1 2025.